Anti-dsDNA antibodies: still a useful criterion for patients with systemic lupus erythematosus?
Anti-dsDNA antibodies: still a useful criterion for patients with systemic lupus erythematosus?
复制标题
DOI：
10.1191/0961203304lu2028oa
复制
发表时间：
2004-01-01
期刊：
影响因子：
2.6
通讯作者：
Isenberg, D
中科院分区：
文献类型：
--
作者：
Isenberg, D
在三种尝试对美国风湿病学院进行的三种尝试中，在每种尝试中，对DsDNA的抗体存在一直是全身性红斑狼疮（SLE）的标准。通常，测试的特异性是，它是相对便宜且易于执行的酶连接的免疫吸附测定法（ELISA）经常进行的，并且经常通过酶连接的免疫吸附测定法（ELISA）进行。然而，抗DSDNA抗体的检测并不是直接的，也不是存在这些抗体的真正意义，它们的真实特异性（或其他方式），即它们是否与疾病致病性真正相关的问题以及它们反映疾病活动的准确性都是过去20年中提出的所有问题。
The presence of antibodies to dsDNA has been a criterion for systemic lupus erythematosus (SLE) in each of three attempts to classify the disease that have been undertaken by the American College of Rheumatology. The generally good specificity of the test, the fact that it is widely available and often undertaken by an enzyme linked immunosorbent assay (ELISA) which is relatively cheap and easy to perform have encouraged its continued presence in the list of lupus criteria. The detection of anti-dsDNA antibodies is not, however, straightforward and the real significance of the presence of these antibodies, their true specificity (or otherwise), the question of whether they are truly linked to disease pathogenicity and how accurately they reflect disease activity are all questions that have been posed in the past 20 years.